Efficacy of probiotic Saccharomyces boulardii as an adjuvant therapy in acute childhood diarrhoea

Journal of Nepal Paediatric Society

Volumn 36, Issue 3, 2016, Pages 250-255

  Dash, Dillip Kumar ^a   Dash, Mrutunjaya ^a   Mohanty, M D ^a   Acharya, Naresh ^a  

^a SIKSHA O ANUSANDHAN DEEMED TO BE UNIVERSITY   (India)

Author keywords

Childhood diarrhoea; Saccharomyces boulardii; Therapy

Indexed keywords

PROBIOTIC AGENT;

ABSENCE OF SIDE EFFECTS; ACUTE DIARRHEA; ADJUVANT THERAPY; ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE DURATION; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; ORAL REHYDRATION THERAPY; RANDOMIZED CONTROLLED TRIAL; SACCHAROMYCES BOULARDII; TERTIARY CARE CENTER;

EID: 85018726912     PISSN: 19907974     EISSN: 19907982     Source Type: Journal    
DOI: 10.3126/jnps.v36i3.15539     Document Type: Article

References (41)

1. Nataro, JP. Diarrhea among children in developing countries. AdvExp Med Biol. 2013;764:73-80 pmid:23654057.
2. World Health Organization: The treatment of diarrhoea: a manual for physicians and other senior health workers, Geneva, 1995, World Health Organization;
3. Centers for Disease Control and Prevention. Diagnosis and Management of Foodborne Illnesses: A Primer for Physicians and Other Health Care Professionals. MMWR 2004; 53 (No. RR-4):[inclusive page numbers].
4. Hill C, Sanders ME. Rethinking “probiotics”. Gut Microbes 2013;4:269-70.
5. Pawlowski, SW, Warren CA, Guerrant R. Diagnosis and treatment of acute or persistent diarrhea. Gastroenterology 2009;136(6):1874-1886 pmid:19457416.
6. World Health Organization. Medicenter.Diarrhoeal disease. April 2013. Available at: www.who.int/mediacentre/factsheets/fs330/en/. Accessed September 14, 2013
7. Pozzoni, P, Riva A, Bellatorre AG, et al. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a singlecenter, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol 2012;107(6):922-931 pmid:22472744.
8. Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF. Probiotics for treating infectious diarrhoea. Cochrane Database Systemic Rev 2004;(2):CD003048.
9. Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, van Belle G. Prevention of antibioticassociated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989;96:981-88.
10. Buts JP, Corthier G, Delmee M. Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants. J PediatrGastroenterolNutr 1993;16: 419-25.
11. Besirbellioglu BA, Ulcay A, Can M, Erdem H, Tanyuksel M, Avci IY, Araz E, Pahsa A. Saccharomyces boulardii and infection due to Giardia lamblia.Scand J Infect Dis 2006;38:479-81.
12. Dahan S; Dalmasso G; Imbert V; Peyron JF; Rampal P; Czerucka D. “Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells”.Infect Immun 2003;71(2):766-73. doi:10.1128/IAI.71.2.766-773.2003.
13. Mansour-Ghanaei F, Dehbashi N, Yazdanparast K, Shafaghi A, 2003. Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World J Gastroenterol 2003;9:1832-833.
14. Center for Disease Control and Prevention: Managing acute gastroenteritis among children, MMWR Recommendations Rep 53:1-33, 2004.
15. Kollaritsch H, Holst H, Grobara P, Wiedermann G. Prevention of travelers’ diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study. Fortsschr Med 1993;111:152-56.
16. Bleichner G, Blehaut H, Mentec H, Moyse D. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. Inten Care Med 1997;23:517-23.
17. Saint-Marc T, Blehaut H, Musial C, Touraine JL. AIDSrelated diarrhea: a double blind trial of Saccharomyces boulardii. Sem Hop 1995;71:735-41.
18. Kurugol Z, Koturoglu G. Effects of Saccharomyces boulardii in children with acute diarrhoea. ActaPaediatr 2005;94:44-7.
19. Billoo AG, Memon MA, Khaskheli SA, Murtaza G, Iqbal K, SaeedShekhani M, Siddiqi AQ. Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea. World J Gastroenterol 2006;12:4557-560.
20. Villarruel G, Rubio DM, Lopez F, Cintioni J, Gurevech R, Romero G, Vandenplas Y. Saccharomyces boulardii in acute childhood diarrhoea: a randomized, placebocontrolled study. ActaPaediatr 2007;96:538-41.
21. Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev GastroenterolHepatol 2010;7:503-14.
22. Szajewska H., Horvath A., Piwowarczyk A. Metaanalysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment PharmacolTher2010;32:1069-79.
23. Czerucka D, Piche T, Rampal P. Review article: yeast as probiotics-Saccharomyces boulardii. Aliment PharmacolTher 2007;26:767-78.
24. Pothoulakis C. Review article: anti-infl ammatory mechanisms of action of Saccharomyces boulardii. Aliment PharmacolTher 2009;30:826-33
25. Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P. Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenicEscherichia coliinfected T84 cells. Infect Immun 2000;68:5998-6004.
26. Szajewska H, Setty M, Mrukowicz J, Guandalini S. Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. J PediatrGastroenterolNutr2006;42:454-75.
27. Szajewska H., Skorka A. (2009) Saccharomyces boulardii for treating acute gastroenteritis in children: updated meta-analysis of randomized controlled trials. Aliment PharmacolTher 2009;30:960-61.
28. McFarland L.V. (2010) Systematic review and metaanalysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 16: 2202-2222 [PMC free article] [PubMed]
29. Bartlett J.G. (2002) Clinical practice. Antibioticassociated diarrhea. N Engl J Med 346: 334-339 [PubMed]
30. McFarland L.V. (2006) Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 101: 812-822 [PubMed]
31. Mansour-Ghanaei F., Dehbashi N., Yazdanparast K., Shafaghi A. (2003) Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World J Gastroenterol 9: 1832-1833 [PMC free article] [PubMed]
32. Gaon D., Garcia H., Winter L. (2003) Effect of Lactobacillus strains and Saccharomyces boulardii on persistent diarrhea in children. Medicina (B Aires) 63: 293-298 [PubMed]
33. McFarland L.V. (2007) Meta-analysis of probiotics for the prevention of traveler’s diarrhea. Travel Med Infect Dis 5: 97-105 [PubMed]
34. Tong J.L., Ran Z.H., Shen J., Zhang C.X., Xiao S.D. (2007) Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment PharmacolTher 25: 155-168 [PubMed]
35. Cain A.M., Karpa K.D. (2011) Clinical utility of probiotics in infl ammatory bowel disease. AlternTher Health Med 17: 72-79 [PubMed]
36. Parkes G.C., Brostoff J., Whelan K., Sanderson J.D. (2008) Gastrointestinalmicrobiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol 103: 1557-1567 [PubMed]
37. Dinleyici E.C., Eren M., Yargic Z.A., Dogan N., Vandenplas Y. (2009) Clinical efficacy of Saccharomyces boulardii and metronidazole compared with metronidazole alone in children with acute bloody diarrhea caused by amebiasis: a prospective, randomized, open label study. Am J Trop Med Hyg 80: 953-955 [PubMed]
38. Elmer G.W., Moyer K.A., Vega R., Surawicz C.M., Collier A.C., Hooton T.M., et al. (1995) Evaluation of Saccharomyces boulardii for patients with HIV-related chronic diarrhoea and in healthy volunteers receiving antifungals. MicrobTher 25: 23-31
39. Buts JP; Bernasconi P; Vaerman JP; Dive C (1990). “Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii”. Dig. Dis. Sci. 35 (2): 251-256. doi:10.1007/BF01536771. PMID 2302983.
40. Buts JP; Bernasconi P; Van Craynest MP; Maldague P; De Meyer R (1986). “Response of human and rat small intestinal mucosa t o doi: 10.1080/003655200750024326. PMID 10720113.oral administration of Saccharomyces boulardii”. Pediatr. Res.20 (2): 192-196. doi:10.1203/00006450-198602000-00020. PMID 3080730.
41. Keya Lahiri, Kapil Jadhav et al 2015, Bacillus Clausii As An Adjuvant Therapy In Acute Childhood Diarrhoea, IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 14, Issue 5 Ver. I (May. 2015), PP 74-76 www.iosrjournals.org